title: Reply to A. Wang-Gillam et al.
authors.affiliation: Davendra P.S. Sohal, Cleveland Clinic, Cleveland, OH; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Daniel Laheru, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; and Alok A. Khorana, Cleveland Clinic, Cleveland, OH.
authors.forename: Davendra P S
authors.initials: DP
authors.lastname: Sohal
authors.affiliation: Davendra P.S. Sohal, Cleveland Clinic, Cleveland, OH; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Daniel Laheru, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; and Alok A. Khorana, Cleveland Clinic, Cleveland, OH.
authors.forename: Pamela B
authors.initials: PB
authors.lastname: Mangu
authors.affiliation: Davendra P.S. Sohal, Cleveland Clinic, Cleveland, OH; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Daniel Laheru, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; and Alok A. Khorana, Cleveland Clinic, Cleveland, OH.
authors.forename: Daniel
authors.initials: D
authors.lastname: Laheru
authors.affiliation: Davendra P.S. Sohal, Cleveland Clinic, Cleveland, OH; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Daniel Laheru, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; and Alok A. Khorana, Cleveland Clinic, Cleveland, OH.
authors.forename: Alok A
authors.initials: AA
authors.lastname: Khorana
mesh_terms: D006801:Humans; D000077146:Irinotecan; D016609:Neoplasms, Second Primary; D010190:Pancreatic Neoplasms; D059004:Topoisomerase I Inhibitors
chemical_list: D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan